BRIEF published on 10/21/2025 at 18:54, 4 months 15 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 4 months 15 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 4 months 30 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
BRIEF published on 10/06/2025 at 14:56, 4 months 30 days ago Threshold Crossing by Bpifrance at ABIONYX PHARMA Voting Rights Actions Threshold Crossing Bpifrance ABIONYX Pharma
BRIEF published on 09/25/2025 at 20:21, 5 months 10 days ago ABIONYX Pharma: Financial results for the first half of 2025 Financial Results Research And Development Treasury France 2030 Plan ABIONYX Pharma
PRESS RELEASE published on 09/25/2025 at 20:16, 5 months 10 days ago Inside Information / News release on accounts, results ABIONYX Pharma announces its 2025 half-year financial results, including revenue of €2.1 million and ongoing initiatives in biotech innovation. Company receives government support for sepsis research Revenue Biotech Innovation ABIONYX Pharma 2025 Financial Results Sepsis Research
BRIEF published on 08/28/2025 at 18:56, 6 months 8 days ago ABIONYX Pharma 2025 half-year review Treasury Financial Support Turnover ABIONYX Pharma Semester 2025
PRESS RELEASE published on 08/28/2025 at 18:51, 6 months 8 days ago Inside Information / Other news releases ABIONYX Pharma provided an update on its activity and cash position for Q2 2025. Company's revenue, cash position, and government funding details revealed Revenue Cash Position Update Government Funding ABIONYX Pharma
BRIEF published on 08/27/2025 at 19:31, 6 months 9 days ago ABIONYX Pharma in talks for a strategic partnership in sepsis Strategic Partnership Innovative Therapies ABIONYX Pharma Sepsis CER-001
PRESS RELEASE published on 08/27/2025 at 19:26, 6 months 9 days ago Inside Information / Other news releases ABIONYX Pharma initiates discussions with a major sepsis player for strategic partnership, aiming to accelerate CER-001 development. Relevance of innovative technology validated Strategic Partnership Innovative Technology ABIONYX Pharma Sepsis CER-001
Published on 03/06/2026 at 00:00, 26 minutes ago Redwood AI Exploring Opportunities for its Proprietary AI Platform Across Multiple Industries
Published on 03/05/2026 at 22:55, 1 hour 31 minutes ago Pivotree to Release Fourth Quarter 2025 Financial Results
Published on 03/05/2026 at 20:00, 4 hours 26 minutes ago PPX Hosts Medical Outreach Campaign for Local Communities
Published on 03/05/2026 at 17:55, 6 hours 31 minutes ago ACCESS Newswire to Host Fourth Quarter and Year End Earnings Conference Call on March 19, 2026
Published on 03/05/2026 at 14:00, 10 hours 26 minutes ago EQ Inc. Secures Strategic Partnership with Global Card Network to Expand Integrated Rewards Across Canada
Published on 03/05/2026 at 19:49, 4 hours 37 minutes ago EQS-Adhoc: Northern Data Announces Preliminary Q4 2025 revenue and FY 2026 outlook
Published on 03/05/2026 at 19:15, 5 hours 11 minutes ago Huawei Wins Eight GLOMO Awards at MWC Barcelona 2026
Published on 03/05/2026 at 19:05, 5 hours 21 minutes ago Supercharging Edge AI: Apacer Launches Industrial Grade Storage for Raspberry Pi Platforms
Published on 03/05/2026 at 18:40, 5 hours 46 minutes ago 2025 Full-year results FREY: a pan-European platform already creating value
Published on 03/05/2026 at 18:34, 5 hours 51 minutes ago Mersen: Number of shares and voting rights as of February 28, 2026
